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We used a sentinel general practitioner (GP) network 
to conduct surveillance for laboratory-confirmed influ-
enza amongst patients presenting with influenza-like 
illness (ILI) in Victoria, Australia in 2011. The test-
negative variation of the case control study design 
was used to estimate effectiveness for seasonal tri-
valent influenza vaccine. Cases and controls were ILI 
patients that tested positive and negative for influ-
enza, respectively. Vaccination status was recorded by 
GPs and vaccine effectiveness (VE) was calculated as 
(1-adjusted odds ratio)x100%. There were 529 patients 
included in the study, of which 29% were influenza-
positive. Twelve percent of study participants were 
reported as vaccinated, 6% of cases and 15% of con-
trols. Adjusted VE against all influenza was 56%, but 
not statistically significant. There was generally little 
variation in VE estimates when stratified by virus type 
and subtype, which is consistent with good matches 
between circulating strains and the vaccine strains. 
The VE was higher among adults of working age than 
among children.
Introduction
Victoria accounts for approximately 25% of Australia’s 
population of 23 million people. It has a temper-
ate climate, and the influenza season usually occurs 
between June and October. Each season, the Victorian 
Infectious Diseases Reference Laboratory uses a net-
work of sentinel general practitioners (GPs) to con-
duct surveillance for influenza-like illness (ILI) and 
laboratory-confirmed influenza. The system has been 
operational since 1998, with an average of 60 GPs par-
ticipating each year. This surveillance system is used 
to estimate vaccine effectiveness (VE) of the seasonal 
influenza vaccine.
Seasonal influenza vaccination in Australia is a pub-
licly funded programme. The Australian government 
provides free influenza vaccination to all Australians 
aged 65 years and older, Aboriginal and Torres Strait 
Islander people over 15 years of age, pregnant women 
and individuals aged six months and older with medi-
cal conditions predisposing to severe influenza [1]. 
Individuals may also be vaccinated outside the funded 
programme, such as through workplaces. The influ-
enza virus composition of the seasonal trivalent 
influenza vaccine (TIV) in Australia in 2011 was A/
California/7/2009 (H1N1)-like virus, A/Perth/16/2009 
(H3N2)-like virus, and B/Brisbane/60/2008-like virus 
(of the B/Victoria/2/87 lineage) [2].
Here we use the results from laboratory-confirmed 
influenza surveillance in Victoria to estimate TIV effec-
tiveness in 2011 using the prospective test-negative 
variation of the case control study. This design has 
been used in Europe, North America and Australia 
[3-6]. We aimed to calculate type- and subtype-specific 
VE estimates and used them in combination with sur-
veillance data to make inferences how well the 2011 
seasonal TIV matched circulating strains. The strain 
composition recommended for use in the 2011 south-
ern hemisphere influenza vaccine was the same as the 
one subsequently used in the 2011/12 northern hemi-
sphere seasonal vaccine [7].
Methods
In 2011, 97 GPs participated in the surveillance system 
which operated from 2 May to 30 October inclusive. 
Advertising in GP circulars was used to encourage GPs 
to participate in the programme and targeted recruit-
ment was undertaken in geographical areas consid-
ered to be poorly represented.  A relatively even and 
widespread distribution suggested adequate represen-
tation of the 97 GPs throughout the metropolitan and 
most rural areas of the state. GPs reported the total 
number of consultations per week from which propor-
tions were calculated as the number of ILI patients per 
1,000 consultations. ILI was defined as fever (or history 
of fever), cough, and either fatigue or malaise [8]. GPs 
were asked to collect a nose and/or throat swab from 
patients with an ILI within four days of the onset of the 
patient’s symptoms and provide data on the patient’s 
age, sex, date of symptoms onset, influenza vaccina-
tion status in 2011 and 2010, date of vaccination and 
presence of comorbid conditions for which influenza 
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vaccination is indicated. Patients were chosen for 
swabbing at the discretion of the GP.
To test for influenza viruses, RNA was extracted from 
clinical specimens using a Corbett extraction robot fol-
lowed by reverse transcription using random hexamers. 
cDNA was amplified using an ABI-7500 Fast Real-Time 
PCR System incorporating primers and probes specific 
for the detection of type A, B and C influenza viruses. 
Samples that tested positive for influenza type A in this 
assay were subtyped in a second real-time PCR assay 
incorporating primers and probe specific for influenza 
A(H1N1)pdm09, A(H1) (non-pandemic) and A(H3) hae-
magglutinin genes.
VE was defined as (1-adjusted odds ratio)x100%, where 
the odds ratio is the ratio of odds of laboratory-con-
firmed influenza cases being vaccinated to the odds 
of controls (those that tested negative for influenza) 
being vaccinated. Logistic regression was used to cal-
culate odds ratios and 95% confidence intervals that 
were adjusted for the variables of age group, month of 
specimen collection and comorbidity. There was not 
sufficient statistical power to generate age-specific 
VE estimates for the age group ≥65 years or to further 
stratify the age group of 0–19 year-olds. Patients were 
excluded from the VE analysis if vaccination status was 
unknown, if the date of symptom onset was unknown or 
if there was an interval greater than four days between 
symptom onset and specimen collection, based on the 
decreased likelihood of a positive result after this time 
[9,10]. Patients were considered not vaccinated if there 
was less than 14 days between the date of vaccination 
and symptom onset. All analyses were conducted using 
Stata (version 10.0; StataCorp LP). The chi-squared test 
was used to compare proportions, with p<0.05 consid-
ered statistically significant.
Results
Participating GPs reported seeing a total of 194,295 
patients during the reporting period, of whom 945 
(0.5%) met the ILI case definition, a proportion that 
was consistent with previous years. As the reporting of 
ILI cases is not identifiable and separate to those who 
are swabbed (for whom data are recorded on a labo-
ratory test request form), we are unable to assess any 
demographic or vaccination status differences between 
those who were swabbed and those who were not. Of 
the 945 ILI cases, 665 (70%) were swabbed and 185 
(28%) tested positive for influenza. In general, influ-
enza A(H1N1)pdm09 predominated during the first half 
of the season, A(H3) during the middle to latter part, 
whilst cases of influenza B were detected throughout 
(Figure). One case of influenza type C infection was 
also detected.
We excluded 136 swabbed patients (20%) from the VE 
analysis due to unknown vaccination status (n=25), 
unknown date of symptom onset (n=44) or more than 
four days between symptom onset and specimen 
Figure
Influenza-positive and -negative patients at sentinel general practices by week, Victoria, 2 May to 30 October (n=665)
0
10
20
30
40
50
60
70
8 
M
ay
15
 M
ay
22
 M
ay
29
 M
ay
5 
Ju
n
12
 Ju
n
19
 Ju
n
26
 Ju
n
3 
Ju
l
10
 Ju
l
17
 Ju
l
24
 Ju
l
31
 Ju
l
7 
Au
g
14
 A
ug
21
 A
ug
28
 A
ug
4 
Se
p
11
 S
ep
18
 S
ep
26
 S
ep
2 
O
ct
9 
O
ct
16
 O
ct
23
 O
ct
30
 O
ct
Nu
m
be
r o
f p
at
ie
nt
s
Week 2011 (weeks ending on given date)
Influenza C
Influenza B
Influenza A, not further specified
Influenza A(H3)
Influenza A(H1N1)pdm09
Negative
3www.eurosurveillance.org
collection (n=80); some were excluded for more than 
one reason. The case of influenza type C infection was 
also excluded. There was no statistically significant 
difference between the swabbed patients that were 
included and those that were excluded from the study 
by vaccination status (p=0.11), influenza positivity 
(p=0.07), age group (p=0.72), presence of a comorbid 
condition (p=0.21) or vaccination in 2010 (p=0.10).
Of the 529 patients included in the study, 155 (29%) 
were cases and 374 (71%) were controls. Cases were 
significantly younger than controls (p=0.004) and 
more common in August and September (p<0.001), 
but there was no statistically significant difference 
between cases and controls by sex (p=0.31) (Table 
1). There was no statistically significant difference 
between cases and controls with respect to presence 
of a comorbidity recommended for influenza vaccina-
tion (p=0.15), although those with a comorbid condi-
tion were more likely to be older (p<0.001) and to be 
vaccinated (p<0.001). Being vaccinated in 2010 was not 
associated with testing positive for influenza (p=0.21), 
but was associated with older age (p<0.001) and with 
vaccination in 2011 (p<0.001).
Of the 529 patients eligible for the VE analysis, 65 
(12%) were reported as vaccinated, with a statistically 
significant difference between cases (6%) and con-
trols (15%) (p=0.008) (Table 2). No cases of influenza 
A(H1N1)pdm09 were reported as vaccinated. The pro-
portion vaccinated was significantly higher in older 
age groups (p<0.001), but there was no statistically 
significant difference between those vaccinated and 
not vaccinated by month of testing (p=0.63).
There was little difference in the overall crude (60%) 
and adjusted (56%) point estimates for VE against all 
influenza, although only the crude estimate was sta-
tistically significant (Table 3). Although slightly higher 
against influenza A(H1N1)pdm09, age-adjusted VE esti-
mates were generally consistent when stratified by 
type and subtype, however, 95% confidence intervals 
for estimates in the age group of 0–19 year-olds were 
very wide. Crude VE against influenza A(H1N1)pdm09 
was 100% because none of 24 cases with confirmed 
influenza A(H1N1)pdm09 were vaccinated, but the VE 
was reduced after adjustment.
A sensitivity analysis conducted by restricting inclusion 
of cases and controls to the influenza season in 2011 
when cases are more likely to be detected (the period 
from 20 June to 30 October when at least one influ-
enza case was detected in consecutive weeks) resulted 
in changes to the point estimates from 0% to 1%. Not 
censoring patients for whom there were more than four 
days between symptom onset and specimen collection 
reduced the crude and overall adjusted VE estimates 
from 0% to 25% and from 2% to 14%, respectively.
Discussion
Using a population of patients with ILI who consulted 
sentinel GPs in Victoria, Australia, we have estimated 
a moderate effectiveness of 56% for the 2011 seasonal 
TIV against all influenza, although this was not statisti-
cally significant. VE estimates for the age group of 0-19 
year-olds (childhood) were lower and considerably less 
precise than those for the age group of 20-64 year-
olds. This is consistent with our observations in pre-
vious years which have highlighted the utility of this 
GP surveillance programme for estimating VE among 
working age adults who comprise most of the surveil-
lance population [11,12].
Table 2
Number and vaccination status of cases and controls by 
age group, vaccine effectiveness study, Victoria, 2 May to 
30 October (n=529)
Age group (years)
0–19 20–64 ≥65 Total
Controls
n 108 249 17 374
Vaccinated (%) 2 (2) 43 (17) 10 (59) 55 (15)
All influenza 
cases
n 67 85 3 155
Vaccinated (%) 1 (1) 6 (7) 3 (100) 10 (6)
Influenza 
A(H1N1)pdm09 
cases
n 4 20 0 24
Vaccinated (%) 0 (0) 0 (0) 0 (0) 0 (0)
Influenza A(H3) 
cases
n 24 29 1 54
Vaccinated (%) 0 (0) 3 (10) 1 (100) 4 (7)
Influenza B 
cases
n 37 30 2 69
Vaccinated (%) 1 (3) 1 (3) 2 (100) 4 (6)
Table 1
Characteristics of cases and controls, vaccine effectiveness 
study, Victoria, 2 May to 30 October (n=529)
Number of 
controls (%)
Number of 
cases (%) p value
Sex
Femalea 189 (51) 86 (55) 0.31
Age
0–19 years 108 (29) 67 (43)
0.00420–64 years 249 (67) 85 (55)
≥65 years 17 (5) 3 (2)
Month of swab collection
May 71 (19) 2 (1)
<0.001
June 64 (17) 1 (<1)
July 59 (16) 30 (19)
August 107 (29) 74 (48)
September 49 (13) 39 (25)
October 24 (6) 9 (6)
Comorbid conditionb 43 (13) 12 (9) 0.15
Previously vaccinatedc 76 (22) 25 (17) 0.21
Total 374 155
a No data for one control.
b No data for 50 controls and 15 cases.
c No data for 27 controls and seven cases.
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Strain typing surveillance data suggested good 
matches to the vaccine strains: 89% of 87 influenza 
A(H1N1) isolates were A/California/7/2009-like with the 
remainder A/California/7/2009-like (low reactor); 96% 
of 122 type A(H3N2) isolates were A/Perth/16/2009-like 
with the remainder A/Perth/16/2009-like (low reactor); 
96% of 136 type B isolates were B/Brisbane/60/2008-
like, 4% were B/Brisbane/60/2008-like (low reactor) 
and fewer than 1% were B/Florida/4/2006-like (low 
reactor) of the B/Yamagata/16/88 lineage (personal 
communication: K O’Bryan, World Health Organization 
Collaborating Centre for Reference and Research on 
Influenza, December 2011). Thus, the type- and sub-
type-stratified VE point estimates are broadly con-
sistent with a good match to the circulating strains. 
However, none of the adjusted VE estimates was statis-
tically significant suggesting insufficient study power. 
This is particularly evident in the childhood age group 
of the 0–19 year-olds.
To our knowledge there are no other published data 
for 2011 southern hemisphere seasonal influenza vac-
cine effectiveness. However, a point of comparison to 
other studies exists given the strain composition has 
not changed for the 2010/11 northern hemisphere and 
2010 and 2011 southern hemisphere seasonal TIVs. 
In general the estimates obtained from our study 
were higher than those from other comparable stud-
ies. Using the same method we were able to demon-
strate an effectiveness of 89% for the 2010 TIV against 
influenza A(H1N1)pdm09 among working age adults 
[12], compared with the 78% effectiveness observed 
this year. A study conducted amongst inpatients in 15 
Australian hospitals in the same period in 2010 esti-
mated a statistically significant effectiveness of 49% 
for TIV against hospitalisation with influenza A(H1N1)
pdm09 [13]. Similarly in Europe, preliminary estimates 
for seasonal influenza vaccine effectiveness against all 
influenza using the test-negative variation of the case 
control study design among ILI patients seen in pri-
mary care were lower than our study, ranging from 5% 
to 50% [14-17]. The pooled end-of-season analysis of 
the European data resulted in lower adjusted estimates 
of VE against both influenza A(H1N1)pdm09 (27%) and 
type B influenza (64%) in working age adults compared 
to our study, although neither was statistically signifi-
cant [18].
In our analysis we attempted to control for variables 
generally considered to be confounders [19], that is, 
those assumed to be associated with both exposure 
(vaccination) and outcome (influenza) but not on the 
causal pathway. These include age, month of swab 
collection and presence of a comorbid condition for 
which influenza vaccine is indicated. We observed gen-
erally little variation between crude VE estimates and 
those adjusted for these confounding variables. Only 
age was significantly associated with both vaccination 
and influenza. Month of swab collection and comor-
bidity were significantly associated with outcome and 
exposure respectively, but neither was significantly 
associated with both. Other studies using the same 
variation of the test-negative case control study as 
this one have also adjusted for receipt of influenza 
vaccine within a year before the study [16,18]. Whilst 
we collected this data field in 2011, its inclusion as a 
covariate in the adjusted model resulted in consider-
able variation from the crude and the age-, month- and 
comorbidity-adjusted VE estimates. However, further 
statistical analysis did not support inclusion of previ-
ous vaccination in the model because it assumes that 
previous vaccination has the same effect regardless of 
vaccination in the current season, and because of its 
high degree of correlation with current vaccination sta-
tus which skews and reduces the precision of the VE 
estimate.
While variables may be considered to be theoreti-
cal confounders they may result in biases that could 
under- or over-estimate the VE. Results from influenza 
VE studies in Europe for the 2010/11 season included 
comments about the need for a cautious approach to 
dealing with such variables [17,20] and highlight the 
need for further clarification of the optimal analysis for 
the test-negative design when used to estimate influ-
enza VE. Whilst relatively new, the method is admin-
istratively practical and theoretically acceptable, and 
Table 3
Crude and adjusted vaccine effectiveness of seasonal vaccine against influenza by age group and type/subtype, Victoria, 2 
May to 30 October (n=529)
Influenza vaccine effectiveness (95% confidence interval)
Crude
Adjusteda
   0–19 years    20–64 years    All ages
All 60 (19 to 80) 33 (-676 to 94) 61 (-3 to 85) 56 (-2 to 81)
Influenza A(H1N1)pdm09 100 (6 to 100)b Not defined 77 (-44 to 100)b,c 78 (-38 to 100)b,c
Influenza A(H3) 54 (-34 to 84) -44 (-1,757 to 100)b,c 48 (-99 to 86) 58 (-53 to 89)
Influenza B 64 (-2 to 88) -16 (-1,298 to 90) 78 (-77 to 97) 53 (-68 to 87)
a Adjusted for month of swab collection and comorbidities.
b Calculated using exact method.
c Median unbiased estimates. 
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we will continue to refine it in collaboration with other 
investigators that have adopted it.
As previously discussed, other limitations of the study 
must also be taken into account when considering the 
results [6,12,21]. Briefly, the study was conducted in a 
general practice setting and the results are thus rep-
resentative of the mid-range of the influenza clinical 
spectrum. Those not sick enough to attend a medical 
practitioner and more severe cases requiring hospitali-
sation were not part of the sampling frame. We were 
unable to quantify immunity from previous infection 
or healthy vaccinee bias, both of which overestimate 
VE. Conversely though, when conducted retrospec-
tively, the test-negative case control design generally 
underestimates true VE under most conditions of test 
sensitivity, specificity and the ratio of influenza to non-
influenza attack rates [22].
Overall, the seasonal TIV was moderately effective 
against medically attended influenza in Victoria, 
Australia during the 2011 southern hemisphere sea-
son. These VE estimates were generally consistent 
among working age adults when stratified by type and 
influenza A subtype, and consistent with an apparent 
good match between TIV and circulating strains during 
a season which saw the re-emergence of the influenza 
A(H3N2) subtype [23].
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